The U.S. Food and Drug Administration granted full approval to Gilead Sciences Inc.’s Trodelvy (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.

Clarivate Analytics pegged 11 drugs set to enter the market during 2020 as potential blockbusters by 2024